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Abstract
This research proposes an innovative data model to determine the landscape of emerging
technologies. It is based on a competitive technology intelligence methodology that incorpo-
rates the assessment of scientific publications and patent analysis production, and is further
supported by experts’ feedback. It enables the definition of the growth rate of scientific and
technological output in terms of the top countries, institutions and journals producing knowl-
edge within the field as well as the identification of main areas of research and development
by analyzing the International Patent Classification codes including keyword clusterization and
co-occurrence of patent assignees and patent codes. This model was applied to the evolving
domain of 3D bioprinting. Scientific documents from the Scopus and Web of Science data-
bases, along with patents from 27 authorities and 140 countries, were retrieved. In total, 4782
scientific publications and 706 patents were identified from 2000 to mid-2016. The number of
scientific documents published and patents in the last five years showed an annual average
growth of 20% and 40%, respectively. Results indicate that the most prolific nations and insti-
tutions publishing on 3D bioprinting are the USA and China, including the Massachusetts Insti-
tute of Technology (USA), Nanyang Technological University (Singapore) and Tsinghua
University (China), respectively. Biomaterials and Biofabrication are the predominant journals.
The most prolific patenting countries are China and the USA; while Organovo Holdings Inc.
(USA) and Tsinghua University (China) are the institutions leading. International Patent Classi-
fication codes reveal that most 3D bioprinting inventions intended for medical purposes apply
porous or cellular materials or biologically active materials. Knowledge clusters and expert
drivers indicate that there is a research focus on tissue engineering including the fabrication of
organs, bioinks and new 3D bioprinting systems. Our model offers a guide to researchers to
understand the knowledge production of pioneering technologies, in this case 3D bioprinting.
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Introduction
Understanding the scientific and technological dynamics behind innovative technologies is
crucial to help organizations in their research and development (R&D) strategic planning. It is
highly valuable, both for present and future decision making, to determine the knowledge
landscape of a research field. This includes statistics relating to the growth of the field—such as
the countries leading in development, the institutions that are the most prolific and the promi-
nent journals—which can be used to determine global technology trends. Over the years,
many studies have assessed the qualitative evolution of scientific technology research and pat-
ents [1–2]. However, this research differs from others [2–3], as it is integrating a novel compet-
itive technology intelligence (CTI) cycle, which focuses on the analysis of both scientific and
technological output and is enriched by the incorporation of experts’ perspectives at different
stages of a project.
Competitive intelligence is based on the systematic and ethical process of gathering, analyz-
ing and transforming information into actionable knowledge in the context of the competitive
environment of an organization. Its main aim is to support decision making and strategic
planning [4]. When technological events are the main focus of analysis, different terms are
used, such as CTI and technology intelligence [5]. Broadly, these terms refer to the process of
monitoring the competitive and technological environment of an organization to support
decisions related to market, innovation, design, and product development [6]. Knowledge pro-
duced by CTI constitutes an important “early warning” for research, development, and even
for innovation [7]. In fact, this process is frequently considered to be a foundational task for
any creative and innovative process [8]. The formal and systematic application of CTI has
gained prominence in technology-based organizations where its influence on producing com-
petitive advantages has been strongly evidenced, through everything from the anticipation of
potential threats to the identification of relevant opportunities for innovation [9]. Feedback
from experts can complement and enhance CTI process from the early stages, which include
the search strategy definition through the analysis and final validation. In this context, a hybrid
CTI + expert perspective data model is proposed in this research in order to perform an analy-
sis of emerging technologies such as 3D bioprinting, a highly innovative technology.
Three-dimensional (3D) printing—also known as additive manufacturing, rapid prototyp-
ing or solid free-form technology—is a revolutionary technology that is bringing important
changes to the world. It involves a process whereby objects are produced by fusing or deposit-
ing materials such as plastic, metal, ceramic, powder, liquid or even living cells, layer-by-layer
from a digital file [10]. The American Society for Testing and Materials (ASTM International)
defines it as “the process of joining materials to make objects from 3D model data, usually
layer upon layer, as opposed to subtractive manufacturing methods” [11]. High quality prod-
ucts with complex geometries and minimal waste can be built, benefiting a variety of sectors
[12]. Applications for 3D printing are found in many fields including education, aerospace,
defense, architecture, transportation, the production of consumer products and healthcare
[13].
Although 3D printing has been used for decades in prototyping [14], 3D bioprinting—
which can be defined as a technique used to print living cells in a predesigned pattern [15]—is
an innovative technology that is still in a nascent stage. The first patent in the field of 3D bio-
printing was granted in 2006 to Clemson University; it protected an invention entitled “ink-jet
printing of viable cells” that consists of a method for developing a viable cell matrix by ink jet
printing onto a substrate [16]. It was not until 2014 that a commercialization of this technology
was developed by the company Organovo Holdings, Inc. [17]. In that year, Organovo success-
fully launched the exVive3D Liver, a liver tissue model for medical and drug research [18].
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3D bioprinting enables the production of elements that repair, replace or control func-
tions within or on the human body, while 3D printing (the general technology without bio-
components) applied to the health sector serves to create prototypes, models, prostheses,
pre-surgery planning tools, alignment jigs and surgical cutting templates. Unquestionably,
3D bioprinting represents a breakthrough technology that can be used to address health
problems, and its applications are growing rapidly [13]. Important efforts are being devoted
to the production of a broad array of state-of-the-art applications such as skin substitutes for
burn wounds [19], elements for urethral reconstruction [20], and components to be used in
place of bones, ears, windpipes, jaw bones, cell cultures, stem cells, blood vessels, vascular
networks, tissues and—in the future—organs [10]. The goals behind recent developments in
3D bioprinting include from the successful application of the technology in bio-clinical
research testing to more importantly its use for the production of fully functioning organs
for transplant [21]. In 2013, a total of 118,114 solid organs were reported to have been trans-
planted worldwide. This represents an increase of approximately 3% over 2012. However, the
scarce availability of organs is evident, as this quantity represents less than 10% of global
need [22]: this is a deficit that could be significantly aided by the application of 3D bioprint-
ing in organ production.
There is still the major challenge of producing not only a superior quality, biocompatible
product for the human body, but also creating live tissues that retain their biological functions.
In fact, the retention of vascularization is one of the biggest problems 3D bioprinting faces, as
it is difficult to mimic the natural blood vessel network that is critical for the long term viability
of any 3D tissue [23].
3D printing has the potential to radically transform the health industry and will generate
major economic and societal impacts [24]. Because of this, scientific output and patent activ-
ity are rapidly growing in 3D bioprinting. Many studies have focused on the fundamentals
and challenges of 3D bioprinting. Ventola [10] presented a review of current and future
applications of this technology, indicating their potential benefits. Yoo [25] analyzed 3D bio-
printing techniques and proposed new potential patenting areas. Also, Sheehan and col-
leagues [26] described a number of bioprinting patents in order to determine general trends
following a qualitative process. Given the major impact that 3D bioprinting may have on
human health, an awareness of the scientific and technological knowledge production
regarding this technology is critical. Nevertheless, studies addressing this are still lacking.
Recently, Trappey and colleagues [27] developed an approach to explore biomedical 3D
printing technology trends, based on an analysis of US patents from 1980 to August 2014.
This study did not consider scientific output nor expert interviews. A study using CTI meth-
odology and applying scientometric and patentometric analyses on 3D bioprinting has not
been undertaken yet. Zhou and colleagues [28] developed a CTI methodology using scientific
and patent production where participation of experts in the field helped to identify research
emphases and trajectories. However, their research focused on nano drug delivery systems.
To fill this gap that has been discussed, and to outline the 3D bioprinting global knowledge
landscape, the research presented here proposes a hybrid data model based on a CTI cycle
integrated with expert perspectives. It is applied to the current state of R&D in 3D bioprint-
ing and considers both scientific literature and patent information from 2000 to mid-2016
from the major authorities worldwide.
The main aims of this study are 1) to provide a novel data model to determine the knowl-
edge landscape of emerging technologies; 2) to apply this model in order to identify scientific
and technology trends in 3D bioprinting; 3) to determine the most prolific countries, organiza-
tions and journals in this domain; and 4) to identify the major research foci.
A 3D bioprinting knowledge landscape
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Methods
Development of a hybrid data model
The approach used in this study was developed as a cyclical process, which is rooted in the
established CTI methodology and comprises 10 main steps that are shown in Fig 1. The meth-
odology starts with a planning process where the main goals, activities, participants and the
allocation of resources are stated. Normally, the party responsible for R&D is also the end user
of the CTI project, thus the goals must align in content and style with the organization’s needs.
The process of development of a CTI activity requires a full understanding of the intelligence
required by the final user and how this intelligence should be delivered [29]. The second stage
consists of the identification of primary and secondary information sources and further source
selection. Primary information comes from experts who are selected by criteria such as their
professional position, number of academic citations, number of highly ranked publications
or general presence in the field. Meanwhile, secondary sources, such as databases and reports,
are also analyzed with regard to their quality and prestige, coverage and completeness of infor-
mation. The next two steps are the definition of the information collection strategy and the
gathering process. These include the determination of the most suitable queries to be used
in retrieving information from databases and their subsequent implementation. This is a fun-
damental step and involves expert consultation from the conception through the validation of
Fig 1. Competitive technology intelligence (CTI) and expert perspective hybrid data model. This flow chart outlines the 10 main steps of the
methodology implemented in the present study. The steps are indicated in boxes and sub-steps are indicated in ovals. The methodology begins
with step one (the planning process) and continues through step 10 (decision making). The steps are repeated iteratively until the desired result has
been obtained.
https://doi.org/10.1371/journal.pone.0180375.g001
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results. The analysis stage follows. This should implement advanced text mining software that
has access to major scientific and patent databases, as well as advanced analytical capabilities
to process thousands of documents to facilitate the determination of the evolution of the field
and its dynamics. Co-occurrence and keywords clusterization techniques are a key part of this
task, and has been used [30] to distinguish the main research areas of a given field.
Next, expert assessment is used to evaluate the search strategy definition, validate the infor-
mation collected and review the analysis stage, which commonly require ratification and
adjustments before arriving at the final results. Insights obtained should be relevant enough to
shed light upon competitive opportunities and threats [5]. Moreover, results should be deliv-
ered according to specific—and previously defined—goals and requirements (for example,
time, format and technical language) demanded by the final customers, in such a way that they
can complete the CTI cycle by making valuable decisions based on the resulting data.
Application of the proposed model to 3D bioprinting
The process described in Fig 1 (see corresponding numbers in parentheses) was implemented
as is explained in the following sections. It began with the process planning stage (1), which
established the activities of the study required to accomplish the main objective, based on this
an identification of information sources (2) was made covering primary (expert) and second-
ary (scientific literature and patents databases) sources. After that, the information collection
strategy (3) including specific queries for databases were stated. Information collection (4)
involved an extensive literature review on 3D printing, 3D bioprinting and tissue engineering.
Additionally, consultations with experts (5) in both academia and industry were performed to
validate results. The scientific literature and patents found were then subjected to a sciento-
metric and patentometric analysis (6), which was again validated by expert feedback (7). The
final results were then verified (8) and adjusted for delivery (9) aiming to contribute the deci-
sion making process (10).
Expert collaboration. Experts in the field of the technology being studied should be
involved in the analysis. For this case, top researchers in 3D bioprinting were identified in the
UK. Locally-based experts were selected primarily from the top 3D bioprinting research
groups at the University of Manchester and the University of Nottingham, based on their
international presence in the field. Qualitative interviews were conducted in person. The
University of Manchester has a long and distinguished history in the development of 3D bio-
printing. An early use of the term “bioprinting” is found in the title of the ‘Workshop on Bio-
printing, Biopatterning and Bioassembly’ held at this university in 2004 [31]. Over the last
several decades, researchers from the University of Manchester have devoted significant efforts
to the advancement of the field, including new bioink technologies and bionano research.
Experts were selected from both the School of Materials, and the School of Mechanical, Aero-
space, and Civil Engineering at the University of Manchester. These experts—who develop
research on 3D bioprinting—were interviewed multiple times from the early stages of the
research to the final results validation. In particular, two researchers were consulted, as they
have more than 6600 and 1500 Scopus citations, respectively, on subjects such as biomaterials,
cell and tissue engineering, cell adhesion, manufacturing of functional components, organ
printing, and bone and cartilage regeneration.
In addition, an important center that aims to influence the worldwide 3D printing research
agenda was identified during the early stages of this research. This is the Engineering and
Physical Sciences Research Council Centre for Innovative Manufacturing in Additive
Manufacturing, which has been hosted by the University of Nottingham in partnership with
Loughborough University since 2012 [32]. This center is developing research that is moving
A 3D bioprinting knowledge landscape
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toward a new generation of additive manufacturing: multifunctional manufacturing, where
multiple dissimilar materials can be printed within a single process. Along this theme, 3D bio-
printing can go beyond the deposition of individual passive components to print entire inte-
grative working systems [33]. Here, many different projects relating to 3D bioprinting are
taking place simultaneously.
Four researchers from the 3D bioprinting research groups at the University of Nottingham
were interviewed. They belong to the Faculty of Engineering and the School of Pharmacy
(Center for Biomolecular Sciences), two of them have more than 760 and 280 Scopus citations,
respectively, on topics related to the generation of micro-structures for tissue engineering,
regenerative medicine, coatings for implants, 3D printing of human tissue, drug delivery sys-
tem, and material-cell interaction, among others.
During all of the steps outlined in Fig 1 experts from both the University of Manchester and
the University of Nottingham provided feedback, predominantly on the analysis and interpre-
tation of scientific documents and patents, including the final validation step.
Search query definition. The definition of a proper search query is crucial especially due
to the fact that emerging technologies encompass different approaches. This task was carried
out through an iterative process whereby different terms and queries were tested by collecting
information from databases and validating the results with experts, as described above. It is
also important to select databases that broadly cover the emerging technology. This study used
the most comprehensive databases available, as is shown in the next section,.
In order to build a search query for 3D bioprinting, we determined specific terms that
occur within the field according to three main groups, as is shown in Fig 2. They are 1) the 3D
printing process itself (3D printing terms), 2) the bioprinting process (bioprinting terms) and
3) the biological words that represent fundamental applications of 3D bioprinting (bioapplica-
tion terms). Previous work by Groll and colleagues [33] on the definitions used in the biofabri-
cation field across scientific disciplines, such as 3D printing, was incorporated. Exclusion
terms were defined based on reports in 3D bioprinting, expert consultations and manual
inspections during query trials.
Each term was tested in different query structures in both the scientific and patent data-
bases. The purpose of this was to identify variations and the pertinence of the information
retrieved. Expert participation was integrated continuously during this activity. Finally, a
global query was determined and is listed in S1 Appendix (‘Global Query’).
Variations on the query are often necessary due to syntax specifications of the different
databases. To delimit the starting year of the information collected from the databases, a deep
literature revision as well as expert consultations should be carried out. In this research we
identified that the first reports of 3D bioprinting were made in early 2000 [34], while “organ
printing” terms referring to the use of 3D printing first appeared in 2003, and the first use of
the term bioprinting was in 2004 [33]. Based on this, 2000 was defined as the initial year for
the gathering stage and 2016 (until July 1st when the information-gathering component of this
research concluded) as the final year.
Scientific literature data collection. The Scopus and Web of Science (WoS) databases
were selected to be used as the primary search engines in this study, as they have the most
extensive coverage of published scientific papers. Scopus is one of the largest abstract and cita-
tion databases of peer-reviewed science and technology literature. It provides access to more
than 5000 publishers worldwide [35]. Likewise, WoS is a database that groups publications
from over 7000 academic and research institutions, including governments and organization
in over 100 countries [36]. As Burnham [37] establishes, both databases are powerful tools and
are complementary as “neither resource is all inclusive”. We recommend these databases for
further CTI studies on emerging technologies.
A 3D bioprinting knowledge landscape
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Fig 2. Main query terminology for the database searches. Words marked with an asterisk (*) are root words, indicating that all possible suffixes
are covered under the query.
https://doi.org/10.1371/journal.pone.0180375.g002
A 3D bioprinting knowledge landscape
PLOS ONE | https://doi.org/10.1371/journal.pone.0180375 June 29, 2017 7 / 22
The main query, defined in the previous section (‘Global Query’ in S1 Appendix), was
adjusted to be used in each of these databases. For this task, a process that included adaptation
to the database-specific syntax and manual validation of the results, as well as expert consulta-
tion, was carried out to determine accuracy. The resulting queries are listed for the respective
databases in S1 Appendix (‘Scopus Query’ and ‘WoS Query’). The Scopus query recovered a
total of 2634 articles and conference proceedings between January 1st, 2000 and July 1st, 2016.
A total of 2148 journal articles and conference proceedings were retrieved for the same period
from the WoS database. The Scopus and WoS exported data can be found in S1 File and S2
File, correspondingly.
Scientific literature data (journal articles and conference proceedings) obtained were mined
with Patent iNSIGHT Pro, a software platform that incorporates advanced text mining algo-
rithms [38]. A total of 4782 documents (Scopus and WoS) published between January 1st,
2000 and July 1st, 2016 were collected, and then followed an extensive cleaning and deduplica-
tion process that retained 4723 unique documents. These data underwent a normalization pro-
cess which consisted of treating synonyms and acronyms as the same word. A “fuzzy match”
algorithm present in the software enabled the identification of similar keywords and assignee
names with 85% coincidence. Specific groups were automatically built based on this criterion.
A further validation of the suitability of each grouping was made through manual inspection
and incorporating experts’ feedback.
Patent collection. This activity was carried out using PatSeer [38], a software program
designed for research, analysis and project management that permits access to more than 92 mil-
lion records from the main patent offices worldwide. It covers bibliographic data from 140 coun-
tries and the full text of 27 authorities including Espacenet (EP), the World Intellectual Property
Organization (WO), the United States Patent and Trademark Office (US) as well as the patent
bodies of Japan (JP), China (CN), Korea (KR), Canada (CA), Germany (DE), France (FR), Great
Britain (GB), Spain (ES), Australia (AU), India (IN), Switzerland (CH), Austria (AT), Brazil
(BR), Thailand (TH), Russia (RU), Philippines (PH), Sweden (SE), Norway (NO), Denmark
(DK), Finland (FI), Belgium (BE), Netherlands (NL), Luxembourg (LU) and Mexico (MX).
As with the scientific literature data search described above, an adaptation of the Global Query
(S1 Appendix) was made to search this patent database and a validation of the results was con-
ducted manually. Patents were searched according to title-abstract-claims (TAC) where the title
and abstract describe the main characteristics of the patent, while the claims section focuses on
how the invention was developed. The final query is listed in S1 Appendix (‘TAC Query’).
A total of 706 documents were found that cover patent applications and grants in 3D bio-
printing filed between January 1st, 2000 and July 1st, 2016. These patents are contained in S3
File. A deduplication process was carried out to eliminate repeated documents. This reduced
the total number of documents to 601. In order to improve the research accuracy, patents were
grouped by families, resulting in 345 patent families (PFs). The European Patent Office [39]
defines PF as “a group of either patent applications or publications made in multiple countries
to protect a single invention by a common inventor(s)”. The first application is made in one
country—the “priority country”—and is then extended to other offices, thus creating a PF.
Results and discussion
In this section, the results obtained through the applied CTI data model are presented.
Scientific publication trends in 3D bioprinting
Scientific knowledge production in 3D bioprinting since the beginning of 2000 was deter-
mined from the results of the corresponding Scopus and WoS analyses: the results are shown
A 3D bioprinting knowledge landscape
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in Fig 3A–3D. The year 2016 is not included in Fig 3A as the results (409 documents) only rep-
resent a partial year (January 1 through July 1). Global results show that 3D bioprinting is rap-
idly gaining attention in R&D, which in turn impacts scientific production: particularly in the
most recent years. While in 2000 there were only 24 scientific publications relating to 3D bio-
printing, this number rose to 792 in 2015, an increase of 3300%. Of the 4314 scientific docu-
ments on 3D bioprinting published from 2000 to 2015, 71% were published in the last five
years (2010–2015), showing the novelty and increasing interest in 3D bioprinting. Within this
same period, there was an annual average growth rate in publications of 20%. In the most
recent years, there was a publication increase of 31% from 2013 to 2014 and an increase of
19% from 2014 to 2015. An exponential regression was done based on the data from 2006 (the
year in which the publication trend began to increase continuously) through 2015. The equa-
tion describing the data was y = 127.13e0.1801x with a coefficient of determination R2 = 0.9823.
Fig 3. Global scientific trends in 3D bioprinting. A summary of the publications on 3D bioprinting that are indexed in Scopus and the Web of Science
according to (A) publication output by year, from 2000 to 2015; (B) the 10 most frequent affiliation countries of the authors; (C) the 10 most frequent
organizational affiliations of the authors (11 institutions are reported due to a tie for tenth place); and (D) the 10 journals with the most occurrences of the
search terms.
https://doi.org/10.1371/journal.pone.0180375.g003
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If the publication increase continues at the same rate, the equation forecasts that 921 docu-
ments will be published in 2016 and 1894 in 2020.
The affiliations of authors of scientific papers indexed in high-impact scientific databases
(such as Scopus or WoS) are an indicator of which countries and organizations have specific
patterns of research concentration and excellence [40]. Here, predominant countries and orga-
nizations in the field of 3D bioprinting are presented. The 10 most prolific nations in terms of
publishing in 3D bioprinting (shown in Fig 3B) are not geographically concentrated. More
than 37% of all publications (1491 documents) come from the USA, and it published over
twice as many documents as the following country, China (744). Likewise, China has close to
double the number of publications as the next most prolific nation, Germany (377). The
remaining countries in the top 10 each published between 167 and 336 documents and are all
located in either western Europe or eastern Asia—with the exception of Australia, which holds
the eighth position.
The top publishing institutions (shown in Fig 3C) are highly correlated with the top 10
countries, as most of these institutions are American (4) and Chinese (3). However, the rank-
ings in this category are much closer in their total output, which indicates that competition is
more active. The top three institutions are the Massachusetts Institute of Technology (USA,
113 documents), Nanyang Technological University (Singapore, 102) and Tsinghua University
(China, 93). The institutes with the next highest levels of output follow closely; top organiza-
tion rankings could vary greatly in the coming years.
Scientific development in 3D bioprinting has led to the creation of new journals focused on
the topic, and consequently the number of scientific publications has increased. An analysis
was made to identify the most prolific 3D bioprinting journals in terms of the volume of docu-
ments published in the field. The top 10 most prolific journals are shown in Fig 3D. Journals
with over 100 published articles or conference proceedings relating to 3D bioprinting are sum-
marized in Table 1. All four of these journals are indexed in the Thomson Reuters Journal
Citation Report [41] under the “engineering, biomedical” and “material science, biomaterials”
categories, with upper quartile rankings.
Patent trends in 3D bioprinting
The patent trends, the patent priority countries and a timeline of patents of the top 10 patent
assignees from January 1st, 2000 to July 1st, 2016, along with the patent’s current legal status
(assigned, granted or inactive), are presented in Fig 4A–4D. The patents obtained were
grouped into PFs, according to the protocol described in the methods section. Text mining
software was used to collect information and followed a similar deduplication, cleaning,
Table 1. Journals with more than 100 articles or conference proceedings on 3D bioprinting.
Position Journal Year of
creation
3D bioprinting
articles
JCR 2015
impact factor
JCR categories ranking
Engineering,
Biomedical
Quartile Material Science,
Biomaterials
Quartile
1 Biomaterials 1980 200 8.387 2/76 1 1/33 1
2 Biofabrication 2009 167 4.702 6/76 1 5/33 1
3 J. Biomedical Materials
Research Part A
1967 127 3.263 13/76 1 14/33 2
4 Acta Biomaterialia 2005 126 6.008 3/76 1 2/33 1
Position is according number of articles published on 3D bioprinting. The Journal Citation Report (JCR) impact factor is the two-year index according to the
2016 JCR citation report.
https://doi.org/10.1371/journal.pone.0180375.t001
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normalization and validation process as was implemented for the scientific literature. In addi-
tion, every PF was manually examined and individually categorized as a patent application,
granted patent or inactive patent. In this period, a total of 345 PFs were detected, with an over-
all application-granted-inactive patent proportion of 70%-17%-13%. Due to the novelty of this
technology, most of the patent applications have not been granted yet.
For the period from 2000 to 2015, 298 PFs in 3D bioprinting were detected and 47 PFs (41
applications, 6 granted, 0 inactive) were found for the first half of 2016. The results in Fig 4A
show rapid growth in the number of patents in this technology. While in 2000 there was only
one PF and none in 2001, the number rose to 97 in 2015, corresponding to an increase of
Fig 4. Publication rates and geographical distribution of 3D bioprinting patents. (A) The number of 3D bioprinting patent families (PFs) by year from
2000 to 2015. (B) The number of 3D bioprinting patents applied for in each of the top 10 most prolific priority countries (i.e. countries in which the first patent
of a PF was applied for). Four countries (Belgium, Canada, India and Japan) were tied for the tenth position. (C) The number of PFs ranked according to
assignee institutions by year, from January 1, 2000 until July 1, 2016. Three institutions (Shandong University, Tongji University and Wuhan University)
were tied for the tenth position. In all three graphs, yellow indicates grants that were applied for, green indicates PFs that were granted, and red indicates
inactive PFs.
https://doi.org/10.1371/journal.pone.0180375.g004
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9700%. An annual average growth rate of 40% was detected from 2010 to 2015. Moreover, this
period contains more than 84% of all PFs. Results obtained show a consistent increase over the
last several years: 65% from 2013 (34 PFs) to 2014 (56 PFs) and 73% from 2014 (56 PFs) to
2015 (97 PFs). As with the 3D bioprinting publication rate, an exponential regression was cre-
ated to describe the rate of patent growth from 2006 to 2015. The resulting equation was
y = 2.1429e0.3628x with a coefficient of determination R2 = 0.9023. If this trend continues, sig-
nificant growth is forecasted for 2016 and 2020, with the number of annual PFs reaching 115
and 494, respectively.
In order to determine the nations of origin of 3D bioprinting PFs, the main countries
where applications were first filed before being (possibly) extended to other countries were
identified. China dominates with 138 PFs during this period (2000-July 1st 2016), as shown in
Fig 4B. It holds an application-granted-inactive ratio of 73%-9%-18%, making it also the coun-
try with the most inactive PFs. The second most PFs come from the USA, with a total of 124
and an application-granted-inactive ratio of 82%-13%-5%. Thus, if the inactive PFs were dis-
carded, the USA would outpace China with 118 vs. 113 PFs, which resembles the results
shown in Fig 3B where the USA ranks highest in terms of total scientific publications on 3D
bioprinting. South Korea has the third most PFs, with 20, and an application-granted-inactive
ratio of 65%-35%-0%. All other countries have produced less than 10 PFs. The overall applica-
tion-granted-inactive ratio for the top 10 priority countries is 73.3%-13.3%-13.3%. The most
significant outliers for granted and inactive PFs are the USA, which holds 36% of all granted
PFs, and China, with 57% of all inactive PFs.
The top patent generating organizations and their patent activity through time are pre-
sented in Fig 4C. Organovo Holdings, Inc. (USA) has the most PFs (11 PFs, of which 6 are
applications, 5 granted and 0 inactive). This is consistent with results from the literature and
expert consultations, where Organovo was identified as the leading company in 3D bioprint-
ing. Founded in 2007, this company designs and creates functional human tissues. It was
founded with the support of patented technologies from the University of Missouri (USA)
[42]: Organovo’s patenting activity in 3D bioprinting was detected in this research from 2012.
Tsinghua University (China) follows with 9 PFs (7 application, 2 granted, 0 inactive), with
its first patent activity during the period assessed found in 2005 and, after years of inactivity, it
recommences patent applications in 2014. Founded in 1911, Tsinghua University has become
one of the biggest and most outstanding Chinese universities. In December 2015, it had 20
schools and 54 departments “with faculties in science, engineering, humanities, law, medicine,
history, philosophy, economics, management, education and art” [43–44] This university has
recently risen to a top position in R&D in 3D bioprinting, as the patent and scientific publica-
tion analyses indicate (Figs 2C and 3C).
In the third position both Therics, LLC. (USA) and Xi’an Jiaotong University (China) have
7 PFs. Therics produced bone substitutes and was founded in 1996 as a subsidiary of Tredegar
Corporation [45]. Therics began its patenting activity early in the period analyzed: between
2000 and 2004, 7 PFs are found, of which 5 are applications and 2 are inactive. After that, pat-
enting efforts ceased and in fact the applications made were never granted. The main reason for
this could be that in 2008 the company was acquired by Integra Life Sciences, a company that
develops solutions for orthopedic extremity surgery, neurosurgery, and reconstructive and gen-
eral surgery [46], but does not work with 3D bioprinting. Xi’an Jiaotong University also has pro-
duced 7PFs, although its rate is different with 3 applications and 4 granted patents. Founded in
1896, this university is an institution focused on the advancement of science and engineering in
a number of fields including new ones such as 3D bioprinting [47]. With patenting activity first
identified in 2010, Xi’an Jiaotong University is the assignee with the second most granted pat-
ents (4, just below Organovo that has 5), and it currently has no inactive patents.
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Global technology trends
Global trends for the countries reveal a prominence of the USA and China in scientific litera-
ture and patent production in 3D bioprinting. The USA has a long tradition of strong invest-
ment in R&D. In the last 20 years, it has increased its R&D expenditure from a 2.4% to 2.7% of
its gross domestic product (GDP). Globally, it is the current leader in net investments in R&D,
with 28% of the global expenditure, reaching a total of $457 billion US dollars [48]. This clearly
has produced a significant effect on the development of breakthrough technologies, such as 3D
bioprinting. However, according to [49], China is rapidly approaching the USA, and is fore-
casted to outpace the country in total expenditures in R&D by 2019. Currently, China ranks
second with 20% of the global expenditure ($369 billion US) on R&D [48].
China’s leading position in science and technology can be explained as a result of specific
government actions implemented over the last decade. In 2006, the Chinese government estab-
lished a 15-year medium-to long-term plan for the development of science and technology
with the goal of rising to the position of an “innovation oriented society” by 2020 and to
become a world leader in science and technology by 2050. According to this plan, China will
invest 2.5% of its increasing GDP in R&D by 2020, up from 1.34% in 2005. Additionally, it
aims to become a top-five country in terms of patenting and most cited papers [50]. As a result
of this government action, China doubled the number of patents it produced in the period
from 2007 to 2012. They also increased their R&D general budget, enforced tax breaks, pro-
moted investments in academic institutions and enhanced monetary incentives [51].
The results presented here have shed light on how 3D bioprinting is attracting the attention
of industry and academia. Scientific and technological research is growing exponentially
thanks to the efforts of large nations such as the USA and China, among others.
An analysis to determine where R&D efforts in 3D bioprinting are focused was developed
in light of patent areas concentration. For this task, the top International Patent Classification
(IPC) patent codes, knowledge areas of research (keyword clusters), and the orientation of
technology efforts of organizations (assignee-IPC patent code co-occurrence) were deter-
mined, as is shown in Fig 5A–5C.
The IPC is an international classification system that provides standard information to cate-
gorize inventions and to evaluate their technological uniqueness [52]. IPC classes enabled the
identification of the main foci of 3D bioprinting inventions. Results show that the most com-
mon IPC section for 3D bioprinting patents is materials for (grafts or) prostheses or for coat-
ing (grafts or) prostheses (A61L27). Within the top 10 classes shown in Fig 5A, 45 PFs relate to
porous or cellular materials (A61L27/56), 37 PFs deal with biologically active materials, e.g.
therapeutic substances (A61L27/54) and shaping techniques not covered by other groups
(B29C67/00), 35 PFs concern animal cells (A61L27/38), 27 PFs refer to macromolecular mate-
rials obtained by means other than by reactions only involving carbon-to-carbon unsaturated
bonds (A61L27/18), 24 PFs deal with materials that are at least partially resorbable by the body
(A61L27/58) and 23 PFs relate to prostheses implantable into the body (A61F2/02). The appli-
cation-granted-inactive ratio is similar to that seen in Fig 4 with 77%-10%-13%, respectively.
In order to complement the summary shown in Fig 5A, a clusterization of keywords was car-
ried out to identify areas where global research in 3D bioprinting is the most active (Fig 5B). The
clusters were produced by extracting raw keywords from the title, abstract and independent
claims of patents and then merging synonyms, eliminating noisy terms, and categorizing the
resulting terms using an algorithm that scans and clusters single concepts in a multi-level hierar-
chy [53]. Each cluster represents a unique concept related to 3D bioprinting, according to the
occurrence of keywords. Therefore, similar terms will not necessarily be placed in the same clus-
ter. Grouping will only occur when the terms share a high co-occurrence.
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Fig 5B shows that the terms within the major knowledge clusters are: tissue engineering
(163 PFs), tissue or organ (67), polylactic acid (46), 3D printer (45), polyethylene glycol (40),
bioink (29), high molecular material (28), bioprint (28), additive manufacturing system (14)
and layer-by-layer self-assembling technology (12). Furthermore, there are clusters that we
consider relevant but that did not reach the top 10. These included alloy powder (10), which
encompasses the terms “titanium alloy” and “porous structure”; double molecule layer (8),
which comprises chemical compounds such as “ethylenediamine” and “chlorosulfonic acid”;
microcapsule (7), which involves chemical terms such as “layers of polypeptides”, “sodium
alginate”, “acid copolymer” and “CaCl2”; and imaging systems (5), which contains terms such
as “laser beam”, “magnetic resonance” and “imaging systems”.
Fig 5. Global technology trends in 3D bioprinting. (A) The top 10 International Patent Classification (IPC) classes in which 3D bioprinting patent
families (PFs) identified in this study are found. (B) The top 10 “knowledge clusters” for IPC 3D bioprinting patents since 2000. The knowledge clusters
were developed using a clustering algorithm based on unique terms occurring in the title, abstract and independent claims of patents. (C) The IPC classes
of patents by each of the top assignees identified in Fig 4. Yellow indicates PFs that have been applied for, green indicates granted PFs and red indicates
inactive PFs. It is important to note that each patent may be listed under several IPC classes, which is why the total number of PFs in (A) and (B) are
greater than the number of PFs presented in (C).
https://doi.org/10.1371/journal.pone.0180375.g005
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The clusters with the highest granted PFs ratio are high molecular material (39%), layer-by-
layer self-assembling technology (33%) and bioprint (32%). This is notable as the average
number of granted PFs in the top 10 clusters in Fig 5B is only 21%. These outliers are likely to
indicate that these aspects of 3D bioprinting technology have flourished. Table 2 shows the
terms included within each of the 10 knowledge clusters presented in Fig 5B.
In order to fulfill the final steps of the hybrid data model, validation of the results and fur-
ther adjustments were made with the support of the previously described experts from the
University of Manchester and the University of Nottingham. Insights revealed that research
on 3D bioprinting is mainly driven by eight key elements. These are depicted in Table 3, where
a direct linkage with the previously obtained knowledge clusters is established.
It is important to point out that clusters result in more focused topics compared to the driv-
ers identified by experts. For example, bioink technology is grouped as a single driver by the
experts, while its components are scattered in different knowledge clusters including bioink,
polylactic acid and polylethylene glycol. This is likely to indicate that an original technology
(bioink) comprises other advancements (polylactic acid and polylethylene glycol). In addition,
clustering differences between experts and text mining approaches reveal how emerging tech-
nologies might be categorized in different ways.
This hybrid approach results in an effective method to validate results. Every top 10 knowl-
edge cluster generated by data mining was contained within the identified drivers by experts,
except for “pharmaceutical research”, a component found in the knowledge cluster ranked
17th as an “anatomical body part”. This knowledge cluster contains the following elements:
• Radiological data
• Active pharmaceutical ingredient
• Magnetic resonance imaging
• Rapidly customizing design
• Successive multi-dimensional digital models
The research organizations’ foci were determined by assessing the top 10 assignees’ co-
occurrence with the top 10 IPC classes (Fig 5C). This shows that the most frequently co-occur-
ring top IPC classes are porous or cellular materials (IPC code A61L27/56), prostheses
implantable into the body (A61F2/02) and macromolecular materials obtained by means other
than by reactions only involving carbon-to-carbon unsaturated bonds (A61L27/18). Of the top
10 assignees, the ones that have the most PFs within the top 10 IPC classes are: Shandong Uni-
versity (China, 16), Quingdao Unique Product Development (China, 12), Therics, LLC. (USA,
10), Massachusetts Institute of Technology (USA, 10) and Tsinghua University (China, 10).
This could indicate that these assignees publish the most focused patents within the top tech-
nological IPC classes. However, the applications-granted-inactive ratio is 83%-8%-9%, which
reveals that the vast majority of the PFs found in the top assignee/IPC class co-occurrence
analysis are recent (in the initial application state).
The data show that 3D bioprinting is still in an early stage and that interest from academia
and industry is evolving and increasingly growing. Given the fact that the patenting process
takes years, only a small number of applications have been granted thus far. In light of these
insights, the results delivery phase can be pursued (Fig 1). It is important to put forward the
results of the goals defined in the initial stage. This includes presenting the content according
to the style defined by the end user: normally the person involved in R&D decision-making.
Conciseness, opportunity and relevance are key aspects of this stage. An executive report can
be produced that condenses the main insights obtained.
A 3D bioprinting knowledge landscape
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Conclusions
This research presents a novel approach to define the knowledge landscape for emerging tech-
nologies. A hybrid data model that combines scientific and technological output analysis and
expert feedback was built. We encourage CTI researchers and professionals to apply this
model for the study of innovative technologies with disruptive potential.
This model was implemented on the ongoing scientific and technology research in 3D
bioprinting. Several reports [12, 14, 54] indicate that this is a promising technology that will rev-
olutionize the health industry as it enables the repair, replacement or control of functions within
or on the human body. Moreover, it is expected that by the late 2020s [54] this technology will
be used to print complex organs, resulting in a sustainable alternative to organ donations.
Blending scientometrics and patentometrics with experts’ insights brings numerous advan-
tages as a CTI approach. It is a symbiotic process and when properly executed, takes the best of
both methods. A more robust process could be developed along all the stages of the model,
Table 3. Linkage between 3D bioprinting drivers identified by experts and knowledge clusters generated through text mining software.
Drivers identified by
experts
Description Knowledge Cluster
Position according to their
number of patent families
Cluster
Tissue engineering Tissue and organ repair, maintenance or replacement through
printing techniques
1 Tissue engineering
2 Tissue or organ
3D bioprinting systems Devices to print molecules, cells, tissues and biodegradable
materials
4 3D printer
9 Additive manufacturing
system
Bioinks Development of new biological, biocompatible and bioabsorbable
materials (polylactic acid, polyethylene glycol and others) that can
be printed while maintaining integrity and structure, and keeping
cells alive
6 Bioink
3 Polylactic acid
5 Polyethylene glycol
10 Layer-by-layer self-
assembling technology
Fibers and scaffolds Development of fundamental structures through 3D bioprinting 7 High molecular material
5 Polyethylene glycol
Human body models Development of models for a better understanding of human body
behavior, including mechanisms that elicit diseases, as well as
those that are part of their prevention and treatment
6 Bioink
8 Bioprint
Regenerative medicine Advancements in regenerative medicine, especially the study of
cancer
4 3D printer
Pharmaceutical research Pharmaceutical research regarding drug dosage modes, delivery
and discovery
17 Anatomical body part
Vascularization
(development of blood
vessels)
Development of new ways to repair and maintain vascularization of
tissues or organs
1 Tissue engineering
2 Tissue or organ
3 Polylactic acid
4 3D printer
7 High molecular material
https://doi.org/10.1371/journal.pone.0180375.t003
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including validation from the early stages where a proper query definition is crucial for the
next steps. It is important to take into account that there are some weaknesses to overcome.
Expert-based methods might become expensive when face-to-face meetings are held. In addi-
tion, experts may inherently carry personal or organizational biases, while computerized tech-
niques show more objectivity [55]. However, to obtain a reliable result it is necessary to have
proper software, with advanced data mining capabilities to process thousands of documents
from myriad formats, as scientific documents and patents are not always consistent in format-
ting. This is expensive, requires a manual cleaning process and effectiveness depends greatly
on the results retrieved from the search query. Thus, assuring the query reliability through
expert validation is crucial to properly execute the CTI approach, which is to generate early
warnings and aid in decision making.
The model applied to 3D bioprinting successfully generated insights that revealed the evolu-
tion of the field according to metrics such as publication and patent behavior, most prolific
nations, top institutions. Additionally, it uncovered the main areas of research. It was found
that both publication and patent rates exhibited exponential growth between 2010 and 2015,
with an average annual growth of 20% and 40%, respectively. Exponential regression indicates
that if the current trends continue, by 2020 there will be 2.4 times more articles and conference
proceedings, and 5 times more patents per year than in 2015. It was also revealed that the USA
and China are currently leading in the total number of scientific publications and patents in
the field, and that there is significant evidence that this trend will continue. The patent analysis,
which took into account the number of patents in different stages (applications, granted and
inactive), revealed that most PFs belonging to top assignees are recent (filed in the last 5 years),
and have not yet passed the application stage. This information highlights the key areas for the
most recent innovations in the field.
One of the most important results was the PF knowledge clusters generated through the
CTI methodology, and the identification of innovation drivers as defined by the experts. They
revealed the strongest trends in current 3D bioprinting research. Tissue and organ engineer-
ing, which refers to the repair, maintenance or replacement of tissue, ranks in the top two posi-
tions in the knowledge clusters, and was also identified by the experts as one of the main
innovation drivers. Bioinks are also currently being patented at a high rate. These are biologi-
cal, biocompatible and bioabsorbable materials, such as polylactic acid and polyethylene glycol,
among others, that can be printed while maintaining their integrity and structure, and keeping
cells alive. New systems for 3D bioprinting are being investigated, as well. Vascularization is
another of the biggest fields of innovation at present. This refers to the development of new
ways to repair and maintain vascularization (development of blood vessels) of tissues or
organs. Moreover, 3D bioprinting is also being used to create anatomical and pharmaceutical
models, and is being used in regenerative medicine as well.
3D bioprinting has great implications for policy makers. 3D printing is an emerging and
promising technology [12] that will enable disruptive innovation in tissue engineering [56]. It
holds tremendous potential for the health industry, especially to address organ donation
demand, and for prevention and regenerative medicine. Future research strategies should
focus on creating more complex tissue or organs, and implement robotic systems to boost pro-
cess productivity to an industrial level [57].
3D bioprinting represents an innovative method for addressing major problems in health.
Early adopters of this technology will have major opportunities in its subsequent use. How-
ever, it is necessary to bear in mind that important challenges are associated with 3D bioprint-
ing. In light of our results that identify the current state of the field, future studies should
identify technological constraints, regulations, standardizations, intellectual property rights
and ethical issues surrounding 3D bioprinting.
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Finally, we have shown how this CTI methodology can be applied to study emerging tech-
nological innovations, such as 3D bioprinting. This case study is just a single example of how
this methodology can be used to assess ongoing research trends and expose the knowledge
landscape. The scope of the methodology is vast, and we expect that it can be successfully
implemented to better understand any emerging technologies that are currently coming onto
the market.
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